Fidelity Investments has significantly lowered the valuation of Juul Labs Inc. in the second quarter due to concerns over the U.S. crackdown on e-cigarettes.
According to data analysis collected by Bloomberg, asset management companies reported that their funds have reduced Juul's valuation by approximately 88%. The data shows that as of June 30th, Fidelity Funds lowered Juul's per share price from $41.01 on March 31st to $4.86, while during the same period, a capital group fund reduced the closely held company's stock price from $52.40 to $6.46.
These cuts have resulted in a series of write-downs for investors as the company undergoes FDA review. Altria Group Inc., the maker of Marlboro cigarettes, spent $12.8 billion in 2018 to acquire a 35% stake in Juul, but as of June 30th, their investment was only worth $450 million. According to PitchBook data, Tiger Global Management and Darsana Capital Partners have also invested in Juul, as has Dan Sundheim's D1 Capital Partners.
Representatives from Fidelity Investment Group declined to comment.
Statement:
This article is compiled based on third-party information and is intended for industry-related communication and learning purposes.
This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the truthfulness or accuracy of the content. The translation of this article is intended only for industry exchange and research.
Due to limitations in our ability to accurately translate, the translated text may differ in expression from the original article. Please refer to the original article for accuracy.
2FIRSTS maintains complete alignment with the Chinese government's positioning and stance on any domestic, cross-border including Hong Kong, Macau and Taiwan, or international issues.
The copyright of compiled information belongs to the original media and author. If there is any infringement, please contact us to have the content removed.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
